Top

Published in:

Open Access 01-06-2010 | Oncology

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline

Authors: Els L. van Persijn van Meerten, Hans Gelderblom, Johan L. Bloem

Published in: European Radiology | Issue 6/2010

Abstract

The purpose of this review article is to familiarize radiologists with the recently revised Response Evaluation Criteria in Solid Tumours (RECIST), used in many anticancer drug trials to assess response and progression rate. The most important modifications are: a reduction in the maximum number of target lesions from ten to five, with a maximum of two per organ, with a longest diameter of at least 10 mm; in lymph nodes (LNs) the short axis rather than the long axis should be measured, with normal LN measuring <10 mm, non-target LN ≥10 mm but <15 mm and target LN ≥15 mm; osteolytic lesions with a soft tissue component and cystic tumours may serve as target lesions; an additional requirement for progressive disease (PD) of target lesions is not only a ≥20% increase in the sum of the longest diameter (SLD) from the nadir but also a ≥5 mm absolute increase in the SLD (the other response categories of target lesion are unchanged); PD of non-target lesions can only be applied if the increase in non-target lesions is representative of change in overall tumour burden; detailed imaging guidelines. Alternative response criteria in patients with hepatocellular carcinoma and gastrointestinal stromal tumours are discussed.

World Health Organization (1979) WHO Handbook for reporting results of cancer treatment. WHO Publication No. 48, Geneva

Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214CrossRefPubMed

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefPubMed

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026 CrossRefPubMed

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586. doi:10.1200/JCO.2006.09.2403 CrossRefPubMed

Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J, Therasse P (2009) Individual patient data analysis to assess modifications of the RECIST criteria. Eur J Cancer 45:248–260. doi:10.1016/j.ejca.2008.10.027 CrossRefPubMed

Moskowitz CS, Jia X, Schwartz LH, Gönen M (2009) A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer 45:300–310. doi:10.1016/j.ejca.2008.11.010 CrossRefPubMed

Schwartz LH, Mazumdar M, Brown W, Smith A, Panicek DM (2003) Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin Cancer Res 9:4318–4323PubMed

Watanabe H, Kunitoh H, Yamamoto S, Kawasaki S, Inoue A, Hotta K, Shiomi K, Kusumoto M, Sugimura K, Saijo N (2006) Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients. Cancer Sci 97:214–218CrossRefPubMed

10.

van Klaveren RJ, Aerts JGJV, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP (2004) Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 43:63–69. doi:10.1016/S0169-5002(3)00292-7 CrossRefPubMed

11.

Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257–260. doi:10.1093/annonc/mdh059 CrossRefPubMed

12.

Plathow Ch, Klopp M, Thieke Ch, Herth F, Thomas A, Schmaehl A, Zuna I, Kauczor H-U (2008) Therapy response in malignant pleural mesothelioma - role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol 18:1635–1643. doi:10.1007/s00330-008-0918-9 CrossRefPubMed

13.

James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P (1999) Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 91:523–528CrossRefPubMed

14.

Trillet-Lenoir V, Freyer G, Kaemmerlen P, Fond A, Pellet O, Lombard-Bohas C, Gaudin JL, Lledo G, Mackiewicz R, Gouttebel MC, Moindrot H, Boyer JD, Chassignol L, Stremsdoerfer N, Desseigne F, Moreau JM, Hedelius F, Moraillon A, Chapuis F, Bleuse JP, Barbier Y, Heilmann MO, Valette PJ (2002) Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol 75:903–908PubMed

15.

Cortes J, Rodriguez J, Diaz-Gonzalez JA, Garzon C, Gurpide A, Arbea L, Gil-Bazo I, Navarro V, Cambeiro M, Nicolas AI, Martin-Algarra S, Garcia-Foncillas J, Calvo E (2002) Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer. Br J Cancer 87:158–160. doi:10.1038/sj.bjc.6600449 CrossRefPubMed

16.

Prasad SR, Saini S, Sumner JE, Hahn PF, Sahani D, Boland GW (2003) Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines. J Comp Ass Tom 27:380–384CrossRef

17.

Mazumdar M, Smith A, Schwartz LH (2004) A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epid 57:358–365. doi:10.1016/j.jclinepi.2003.07.015 CrossRef

18.

Schwartz LH, Colville JAC, Ginsberg MS, Wang L, Mazumdar M, Kalaigian J, Hricak H, Ilson D, Schwartz GK (2006) Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. Ann Oncol 17:1018–1023. doi:10.1093/annonc/mdl058 CrossRefPubMed

19.

Belton AL, Saini S, Liebermann K, Boland GW, Halpern EF (2003) Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. Clin Radiol 58:311–314. doi:10.1016/S0009-9260(02)00577-9 CrossRefPubMed

20.

Hopper KD, Kasales CJ, Van Slyke MA, Schwartz TA, TenHave TR, Jozefiak JA (1996) Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR Am J Roentgenol 167:851–854PubMed

21.

Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, Munden RF (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21:2574–2582. doi:10.1200/JCO.2003.01.144 CrossRefPubMed

22.

Wormanns D, Kohl G, Klotz E, Marheine A, Beyer F, Heindel W, Diederich S (2004) Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility. Eur Radiol 14:86–92. doi:10.1007/s00330-003-2132-0 CrossRefPubMed

23.

Gietema HA, Schaefer-Prokop CM, Mali WPTM, Groenewegen G, Prokop M (2007) Pulmonary nodules: interscan variability of semiautomated volume measurements with multisection CT—influence of inspiration level, nodule size, and segmentation performance. Radiology 245:888–894CrossRefPubMed

24.

Marten K, Auer F, Schmidt S, Kohl G, Rummey EJ, Engelke C (2006) Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. Eur Radiol 16:781–790. doi:10.1007/s00330-005-0036-x CrossRefPubMed

25.

Keil S, Behrendt FF, Stanzel S, Sühling M, Koch A, Bubenzer J, Mühlenbruch G, Mahnken AH, Günther RW, Das M (2008) Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices. Comparison of semi-automated and manual measurement of RECIST and WHO criteria. Eur Radiol 18:2456–2465. doi:10.1007/s00330-008-1050-6 CrossRefPubMed

26.

Fabel M, von Tengg-Kobligk H, Giesel FL, Bornemann L, Dicken V, Kopp-Schneider A, Moser C, Delorme S, Kauczor H-U (2008) Semi-automated volumetric analysis of lymph nod metastases in patients with malignant melanoma stage III/IV—a feasibility study. Eur Radiol 18:1114–1122. doi:10.1007/s00330-008-0866-4 CrossRefPubMed

27.

Ertl-Wagner BB, Blume JD, Peck D, Udupa JK, Herman B, Levering A, Schmalfuss IM (2009) Reliability of tumor volume estimation from MR images in patients with malignant glioma. Results from the American College of Radiology Imaging Network (ACRIN) 6662 trial. Eur Radiol 19:599–609. doi:10.1007/s00330-008-1191-7 CrossRefPubMed

28.

Sargent DJ, Rubinstein L, Schwartz L, Dancey JE, Gatsonis G, Dodd LE, Shankar LK (2009) Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 45:290–299. doi:10.1016/j.ejca.2008.10.030 CrossRefPubMed

29.

McHugh K, Kao S (2003) Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology? Br J Radiol 76:433–436. doi:10.1259/bjr/15521966 CrossRefPubMed

30.

Therasse P, Eisenhauer EA, Verweij J (2006) RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42:1031–1039. doi:10.1016/j.ejca.2006.01.026 CrossRefPubMed

31.

Husband JE, Schwartz LH, Spencer J, Ollivier L, King DM, Johnson R, Reznik R (2004) Evaluation of the response to treatment of solid tumours—a consensus statement of the International Cancer Imaging Society. Br J Cancer 90:2256–2260PubMed

32.

Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB (1985) Normal mediastinal lymph nodes: number and size according to American Thoracic Society Mapping. AJR Am J Roentgenol 144:261–265PubMed

33.

Matsuoka H, Masaki T, Sugiyama M, Atomi Y, Ohkura Y, Sakamoto A (2007) Morphological characteristics of lateral pelvic lymph nodes in rectal carcinoma. Langenbecks Arch Surg 392:543–547. doi:10.1007/s00423-007-0181-6 CrossRef

34.

Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, Gwyther S, Eisenhauer EA (2009) Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 45:261–267. doi:10.1016/j.ejca.2008.10.028 CrossRefPubMed

35.

Dorfman RE, Alpern MB, Gross BH, Sandler MA (1991) Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology 180:310–322

36.

McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JAO, Moore EH, Wain JC, Mathisen DJ, Grillo HC (1992) Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 182:319–323PubMed

37.

Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vandeberg B, Lecouvet FE (2005) Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 65:178–187. doi:10.1002/pros.20280 CrossRefPubMed

38.

Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinksy E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O’Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of Sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512. doi:10.1200/JCO.2005.03.6723 CrossRefPubMed

39.

Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Suk Heist R, Clark JR Lynch TJ (2008) A phase II study of Gefitinib in patients with advanced thyroid cancer. Thyroid 18:317–323. doi:10.1089/thy.2007.0120 CrossRefPubMed

40.

Shephard FA, Rodrigues Pereira J, Ciuleanu T, Huat Tan E, Hirsch V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, for the National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132CrossRef

41.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IGH, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ, for the Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281CrossRefPubMed

42.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMed

43.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AZ, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711. doi:10.1093/jnci/djn134 CrossRefPubMed

44.

Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with Imatinib Mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759. doi:10.1200/JCO.2006.07.3049 CrossRefPubMed

45.

Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA Charnsangavej C (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760–1764. doi:10.1200/JCO.2006.07.3411 CrossRefPubMed

46.

Kawamoto S, Permpongkosol S, Bluemke DA, Fishman EK, Solomon SB (2007) Sequential changes after radiofrequency ablation and cryoablation of renal neoplasms: role of CT and MR imaging. Radiographics 27:343–355. doi:10.1148/rg.272065119 CrossRefPubMed

47.

Kim Y-S, Rhim H, Lim HK (2009) Imaging after radiofrequency ablation of hepatic tumors. Semin Ultrasound CT MRI 30:49–66. doi:10.1053/j.sult.2008.12.004 CrossRef

48.

Weber WA (2009) Assessing tumor response to therapy. J Nucl Med 50:1S–10S. doi:10.2967/jnumed.108.057174 CrossRefPubMed

49.

Hutchings M, Barrington SF (2009) PET/CT for therapy response assessment in lymphoma. J Nucl Med 50:21S–30S. doi:10.2967/jnumed.108.057190 CrossRefPubMed

50.

Hicks RJ (2009) Role of F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 50:31S–42S. doi:10.2967/jnumed.108.057216 CrossRefPubMed

51.

de Geus-Oei L-F, Vriens D, van Laarhoven HWM, van der Graaf WTA, Oyen WJG (2009) Monitoring and predicting response to therapy with ¹⁸F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50:43S–54S. doi:10.2967/jnumed.108.057224 CrossRefPubMed

52.

Avril N, Sassen S, Roylance R (2009) Response to therapy in breast cancer. J Nucl Med 50:55S–63S. doi:10.2967/JNUMED.108.057240 CrossRefPubMed

53.

Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50:11S–20S. doi:10.2967/jnumed.108.057182 CrossRefPubMed

54.

Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S–150S. doi:10.2967/jnumed.108.057307 CrossRefPubMed

55.

Galbraith SM, Rustin GJS, Lodge MA, Taylor J, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20:3826–3840. doi:10.1200/JCO.2002.09.144 CrossRefPubMed

56.

van Rijswijk CSP, Geirnaerdt MJA, Hogendoorn PCW, Peterse JL, van Coevorden F, Taminiau AHM, Tollenaar RAEM, Kroon BBR, Bloem JL (2003) Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results. Eur Radiol 13:1849–1858. doi:10.1007/s00330-002-1785-4 CrossRefPubMed

57.

O’Connor JPB, Jackson A, Parker GJM, Jayson GC (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96:189–195. doi:10.1038/sj.bjc.6603515 CrossRefPubMed

58.

Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManns K, Price RR, Gore JC (2007) Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Res Imag 25:1–13. doi:10.1016/j.mri.2006.09.006 CrossRef

59.

Padhani AR, Liu G, Mu-Koh D, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammond DA, Rustin GJS, Taouli B, Choyke PL (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125. doi:10.1593/neo.81328 PubMed

60.

Kan Z, Phongkitkarun S, Kobayashi S, Tang Y, Ellis LM, Lee TY, Charnsangavej C (2005) Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 237:151–158. doi:10.1148/radiol.2363041293 CrossRefPubMed

61.

Meijerink MR, van Cruijsen H, Hoekman K, Kater M, van Schaik C, van Waesberghe JHTM, Giaccone G, Manuliu RA (2007) The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 17:1700–1713. doi:10.1007/s00330-006-0425-9 CrossRefPubMed

62.

Kambadakone AR, Sahani DV (2009) Body perfusion CT: technique, clinical applications and advances. Radiol Clin N Am 47:161–178. doi:10.1016/j.rcl.2008.11.003 CrossRefPubMed

Title: RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
Authors: Els L. van Persijn van Meerten
Hans Gelderblom
Johan L. Bloem
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: European Radiology / Issue 6/2010
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-009-1685-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2010

Primary giant cell tumor of soft tissue: fluid-fluid levels at MRI (2010:3b)

Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI

Feasibility of contrast material volume reduction in coronary artery imaging using 320-slice volume CT

T2 and T2* mapping in patients after matrix-associated autologous chondrocyte transplantation: initial results on clinical use with 3.0-Tesla MRI

Does joint alignment affect the T2 values of cartilage in patients with knee osteoarthritis?

Assessment of vascular invasion by bone and soft tissue tumours of the limbs: usefulness of MDCT angiography